CliffBio
small molecule

NINTEDANIB ESYLATE

NINTEDANIB ESYLATE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameNINTEDANIB ESYLATE
Active ingredientNINTEDANIB ESYLATE
StrengthEQ 150MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2026
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NINTEDANIB ESYLATE patent cliff — loss of exclusivity — | CliffBio